Evidence map›Paper›PMID 14982854›Full record

ArticleThe American journal of pathology2004

Transforming growth factor-beta1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: a key event in muscle fibrogenesis.

Yong Li, William Foster, Bridget M Deasy, Yisheng Chan, Victor Prisk, Ying Tang, James Cummins, Johnny Huard

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in The American journal of pathology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05637216 (A Pilot Study of Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients), which is not on this map. Cited by 206 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
206citing papers in PubMed, 1 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05637216 phase2active not recruitingnot on this mapstarted 2023, after this paper: background citation

A Pilot Study of Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients

TypeinterventionalSponsorShaw Cancer CenterRan2023 to 2027Enrolled43ConditionsRadiation Induced FibrosisArmsLosartan 25 milligram capsule, Placebo
3 · Its place in the literature

Who cites it

206 citing papers in PubMed, 1 synthesis or guideline pooled it, 444 citations in OpenAlex.

  1. Skeletal muscle alterations in Marfan syndrome: a systematic review.Journal of muscle research and cell motility · 2025
    Pooled it
  2. Trial
  3. Review
  4. Article
  5. Regenerative Medicine: Advanced Therapy for Muscle Tissue Restoration.International journal of molecular sciences · 2026
    Review
  6. Review
  7. The role of sestrin2 in skeletal muscle regeneration after injury.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2026
    Article
  8. Article
  9. Review
  10. Regulatory role of vitamin DScientific reports · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

146 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yong LiGrowth and Development Laboratory, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania 15213-2583, USA. jhuard+@pitt.edu
William Foster
Bridget M Deasy
Yisheng Chan
Victor Prisk
Ying Tang
James Cummins
Johnny Huard
Children's Hospital of Pittsburgh · US

Funding

IMPROVING MUSCLE HEALING THROUGH PREVENTION OF FIBROSISR01AR047973 · NIAMS · CHILDREN'S HOSP PITTSBURGH/UPMC HLTH SYS · PI HUARD, JOHNNY · 2001 to 2004
$1.1M
NIAMS NIH HHS 1R01 AR 47973-01NIAMS NIH HHS R01 AR047973
6 · The paper itself

Abstract

Transforming growth factor-beta1 (TGF-beta1) is thought to play a crucial role in fibrotic diseases. This study demonstrates for the first time that TGF-beta1 stimulation can induce myoblasts (C2C12 cells) to express TGF-beta1 in an autocrine manner, down-regulate the expression of myogenic proteins, and initiate the production of fibrosis-related proteins in vitro. Direct injection of human recombinant TGF-beta1 into skeletal muscle in vivo stimulated myogenic cells, including myofibers, to express TGF-beta1 and induced scar tissue formation within the injected area. We also observed the local expression of this growth factor by myogenic cells, including regenerating myofibers, in injured skeletal muscle. Finally, we demonstrated that TGF-beta1 gene-transfected myoblasts (CT cells) can differentiate into myofibroblastic cells after intramuscular transplantation, but that decorin, an anti-fibrosis agent, prevents this differentiation process by blocking TGF-beta1. In summary, these findings indicate that TGF-beta1 is a major stimulator that plays a significant role in both the initiation of fibrotic cascades in skeletal muscle and the induction of myogenic cells to differentiate into myofibroblastic cells in injured muscle.

Indexed as

AnimalsBlotting, WesternCell DifferentiationDecorinEnzyme-Linked Immunosorbent AssayExtracellular Matrix ProteinsFibrosisHumansImmunohistochemistryMiceMuscle CellsMuscle, SkeletalProteoglycansReverse Transcriptase Polymerase Chain ReactionTransfectionTransforming Growth Factor betaDCN protein, humanDcn protein, mouseDecorinExtracellular Matrix ProteinsProteoglycansTGFB1 protein, humanTgfb1 protein, mouseTransforming Growth Factor betaTransforming Growth Factor beta1

Identifiers

PMID14982854
PMCPMC1614716
OpenAlexW1997639385

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.